Evidence map›Paper›PMID 32095916›Full record

ArticlePsychopharmacology2020

Effects of combined 5-HT

Adriana M Marques, Michele V Macena, Aline R Cardoso, Camila S O Hammes, Fernanda M L Pinheiro, Newton G Castro, Gilda A Neves

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Adriana M MarquesLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.
Michele V MacenaLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.
Aline R CardosoLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.
Camila S O HammesLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.
Fernanda M L PinheiroLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.
Newton G CastroLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil.ORCID http://orcid.org/0000-0001-9570-7428
Gilda A NevesLaboratory of Molecular Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, bloco J, sala J1-029, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, CEP 21941-902, Brazil. ganeves@icb.ufrj.br.ORCID http://orcid.org/0000-0002-7027-3851
Universidade Federal do Rio de Janeiro · BR

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/110.435/2014Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/110.678/2012
6 · The paper itself

Abstract

rationalePrepulse inhibition of the startle reflex (PPI) is disrupted in several psychiatric disorders including schizophrenia. Understanding PPI pharmacology may help elucidate the pathophysiology of these disorders and lead to better treatments. Given the advantages of multi-target approaches for complex mental illnesses treatment, we have investigated the interaction between receptors known to modulate PPI (5-HT

objectivesTo investigate serotonin and cannabinoid receptor (CBR) co-modulation in a model of PPI disruption relevant to schizophrenia

methodsMale Swiss mice were pretreated with WIN 55,212-2 (CBR agonist), rimonabant (CB1R inverse agonist), 8-OH-DPAT (5-HT

resultsWIN 55,212-2 and rimonabant did not change PPI nor block MK-801-induced deficits. 8-OH-DPAT increased PPI in control mice and, in a higher dose, inhibited MK-801-induced impairments. Volinanserin also increased PPI in control and MK-801-treated mice, presenting an inverted U-shaped dose-response curve. Co-administration of either cannabinoid ligand with 8-OH-DPAT did not change PPI; however, the combination of volinanserin with rimonabant increased PPI in both control and MK-801-exposed mice.

conclusionsWIN 55,212-2 and rimonabant had similar effects in PPI. Moreover, serotonin and cannabinoid receptors interact to modulate PPI. While co-modulation of CBR and 5-HT

Indexed as

8-Hydroxy-2-(di-n-propylamino)tetralinAnimalsBenzoxazinesCannabinoid Receptor AntagonistsCannabinoid Receptor ModulatorsCannabinoidsDose-Response Relationship, DrugDrug Therapy, CombinationFluorobenzenesMaleMiceMorpholinesNaphthalenesPiperidinesPrepulse InhibitionReceptors, Cannabinoid(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone8-Hydroxy-2-(di-n-propylamino)tetralinBenzoxazinesCannabinoid Receptor AntagonistsCannabinoid Receptor ModulatorsCannabinoidsFluorobenzenesMorpholinesNaphthalenesPiperidinesReceptors, CannabinoidReceptor, Serotonin, 5-HT2ASerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonistsvolinanserin5-HT1A receptor5-HT2A receptorCB1 receptorMulti-target approachPrepulse inhibitionPsychosisSchizophreniaSensorimotor gating

Identifiers

PMID32095916
OpenAlexW3008620996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.